BioSpace News Archive

The rapid advancement of technology has propelled the field of life sciences into unprecedented growth, constantly expanding our understanding and imagination.

Owens & Minor, Inc. has unveiled its new purpose, Life Takes Care. More than a motto or tagline, Life Takes Care captures the company’s unique approach to caring for both the business and the humanity at the heart of healthcare.

BD (Becton, Dickinson and Company) today announced it has received 510(k) clearances from the U.S. Federal Drug Administration (FDA) for a novel blood collection device that obtains blood samples from a fingerstick that produce lab-quality results for some of the most commonly ordered blood tests.

Solid Biosciences Inc. today announced that it has received Fast Track Designation from the U.S. Food and Drug Administration (FDA) for SGT-003.

AltruBio Inc. today announced the first patient enrolled for the Phase 2a clinical study of the company’s subcutaneously administered immune checkpoint enhancer (ICE), ALTB-268 in ulcerative colitis (UC).

Cidara Therapeutics, Inc. today announced the presentation of new preclinical data on its novel, multi-specific CD73/PD-1 targeting drug-Fc conjugate (DFC) candidate at the ESMO Immuno-Oncology (IO) Annual Congress.

BrainsWay Ltd., a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, announced expanded availability of its Deep Transcranial Magnetic Stimulation technology in South Korea.

Phio Pharmaceuticals Corp. today announced the agreement by several accredited investors to exercise certain outstanding warrants to purchase up to an aggregate of 2,130,252 shares of common stock of the Company originally issued in October 2018 through June 2023.

Vittoria Biotherapeutics has announced the clearance of an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for the initiation of a first-in-human Phase 1 clinical trial to evaluate the Company’s lead candidate, VIPER-101, a gene-edited, autologous, CAR-T cell therapy for treatment of patients with relapsed or refractory T-cell lymphoma.

Hepion Pharmaceuticals, Inc. today announced that its Board of Directors has approved a strategic restructuring plan with the objective of preserving capital by initially reducing operating costs by approximately 60% going forward.